Audentes Therapeutics Stock Price, News & Analysis (NASDAQ:BOLD)

$33.51 -0.78 (-2.27 %)
(As of 02/20/2018 10:30 AM ET)
Previous Close$33.51
Today's Range$33.01 - $34.11
52-Week Range$13.90 - $41.80
Volume116,800 shs
Average Volume510,548 shs
Market Capitalization$1.22 billion
P/E Ratio-9.60
Dividend YieldN/A
Beta0.41

About Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics logoAudentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Receive BOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BOLD
CUSIPN/A
Phone415-638-6556

Debt

Debt-to-Equity RatioN/A
Current Ratio12.04%
Quick Ratio12.04%

Price-To-Earnings

Trailing P/E Ratio-9.60169168569718
Forward P/E Ratio-9.57
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($4.62) per share
Price / Book-7.25

Profitability

Trailing EPS($3.49)
Net Income$-59,660,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-52.43%

Miscellaneous

Employees97
Outstanding Shares36,470,000

Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) announced its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.88). View Audentes Therapeutics' Earnings History.

Where is Audentes Therapeutics' stock going? Where will Audentes Therapeutics' stock price be in 2018?

9 Wall Street analysts have issued twelve-month price targets for Audentes Therapeutics' stock. Their predictions range from $23.00 to $56.00. On average, they anticipate Audentes Therapeutics' stock price to reach $35.38 in the next twelve months. View Analyst Ratings for Audentes Therapeutics.

Are investors shorting Audentes Therapeutics?

Audentes Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,655,460 shares, an increase of 71.6% from the January 12th total of 964,664 shares. Based on an average daily trading volume, of 633,577 shares, the short-interest ratio is currently 2.6 days. Currently, 6.9% of the shares of the stock are short sold.

Who are some of Audentes Therapeutics' key competitors?

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the folowing people:

  • Matthew R. Patterson, President, Chief Executive Officer, Co-Founder, Director (Age 45)
  • Thomas J. Schuetz M.D. Ph.D., Co-Founder, Independent Director (Age 56)
  • Thomas P. Soloway, Chief Financial Officer, Senior Vice President (Age 49)
  • Natalie C. Holles, Chief Operating Officer, Senior Vice President (Age 43)
  • David Nagler, Senior Vice President - Human Resources and Corporate Affairs (Age 63)
  • John Gray Ph.D., Senior Vice President - Research and Development (Age 53)
  • Mary Newman, Senior Vice President - Regulatory Affairs (Age 58)
  • Suyash Prasad, Senior Vice President, Chief Medical Officer (Age 47)
  • Mark Goldberg M.D., Director
  • Jennifer Jarrett, Director

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an initial public offering (IPO) on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who owns Audentes Therapeutics stock?

Audentes Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.83%), Versant Venture Management LLC (4.04%), Redmile Group LLC (2.56%), Jennison Associates LLC (2.86%), Alliancebernstein L.P. (1.26%) and Franklin Resources Inc. (0.96%). Company insiders that own Audentes Therapeutics stock include 5Am Partners Iii, Llc, David Nagler, James E Flynn, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc, Suyash Prasad and Versant Ventures Iv, Llc. View Institutional Ownership Trends for Audentes Therapeutics.

Who sold Audentes Therapeutics stock? Who is selling Audentes Therapeutics stock?

Audentes Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, Redmile Group LLC, Alliancebernstein L.P., Driehaus Capital Management LLC, Ascend Capital LLC, Franklin Resources Inc., Ardsley Advisory Partners and Metropolitan Life Insurance Co. NY. Company insiders that have sold Audentes Therapeutics company stock in the last year include David Nagler, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Insider Buying and Selling for Audentes Therapeutics.

Who bought Audentes Therapeutics stock? Who is buying Audentes Therapeutics stock?

Audentes Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Citadel Advisors LLC, BlackRock Inc., Two Sigma Investments LP, Goldman Sachs Group Inc., Renaissance Technologies LLC, Essex Investment Management Co. LLC and Deutsche Bank AG. Company insiders that have bought Audentes Therapeutics stock in the last two years include 5Am Partners Iii, Llc, James E Flynn, Orbimed Advisors Llc and Versant Ventures Iv, Llc. View Insider Buying and Selling for Audentes Therapeutics.

How do I buy Audentes Therapeutics stock?

Shares of Audentes Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Audentes Therapeutics' stock price today?

One share of Audentes Therapeutics stock can currently be purchased for approximately $33.51.

How big of a company is Audentes Therapeutics?

Audentes Therapeutics has a market capitalization of $1.22 billion. The biotechnology company earns $-59,660,000.00 in net income (profit) each year or ($3.49) on an earnings per share basis. Audentes Therapeutics employs 97 workers across the globe.

How can I contact Audentes Therapeutics?

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-638-6556 or via email at [email protected]


MarketBeat Community Rating for Audentes Therapeutics (BOLD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  224
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Audentes Therapeutics (NASDAQ:BOLD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.882.803.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $35.38$36.71$28.00$22.25
Price Target Upside: 7.85% upside9.11% upside8.78% upside23.34% upside

Audentes Therapeutics (NASDAQ:BOLD) Consensus Price Target History

Price Target History for Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics (NASDAQ:BOLD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018MizuhoInitiated CoverageNeutral -> Neutral$26.00MediumView Rating Details
2/7/2018HC WainwrightReiterated RatingBuy$37.00HighView Rating Details
1/4/2018Raymond James FinancialReiterated RatingHoldHighView Rating Details
1/5/2018BMO Capital MarketsSet Price TargetBuy$44.00HighView Rating Details
1/5/2018William BlairReiterated RatingBuyHighView Rating Details
1/4/2018WedbushBoost Price TargetOutperform$56.00HighView Rating Details
11/15/2017Leerink SwannReiterated RatingOutperform$22.00 -> $29.00N/AView Rating Details
9/22/2017Bank of AmericaReiterated RatingBuy$23.00 -> $33.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$23.00LowView Rating Details
11/12/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
8/15/2016CowenInitiated CoverageOutperformN/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Audentes Therapeutics (NASDAQ:BOLD) Earnings History and Estimates Chart

Earnings by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics (NASDAQ BOLD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.88)($0.88)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.77)($0.87)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.92)($0.83)ViewN/AView Earnings Details
3/9/201712/31/2016($0.75)($0.91)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.66)($0.94)ViewN/AView Earnings Details
8/31/2016Q2 2016($1.35)($6.43)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Audentes Therapeutics (NASDAQ:BOLD) Earnings Estimates

2018 EPS Consensus Estimate: ($3.33)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.84)($0.78)($0.81)
Q2 20183($0.85)($0.80)($0.83)
Q3 20183($0.86)($0.81)($0.84)
Q4 20183($0.88)($0.83)($0.86)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Audentes Therapeutics (NASDAQ:BOLD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Audentes Therapeutics (NASDAQ BOLD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 47.30%
Institutional Ownership Percentage: 67.36%
Insider Trades by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics (NASDAQ BOLD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/22/2017Louis G LangeDirectorSell18,000$30.88$555,840.00View SEC Filing  
12/1/2017Suyash PrasadVPSell8,000$28.53$228,240.00View SEC Filing  
11/16/2017Mary NewmanSVPSell10,000$26.84$268,400.00View SEC Filing  
10/2/2017Matthew R PattersonCEOSell25,000$27.92$698,000.00View SEC Filing  
9/29/2017Louis G LangeDirectorSell11,000$28.35$311,850.00441,555View SEC Filing  
9/29/2017Orbimed Advisors LlcMajor ShareholderSell672,000$28.25$18,984,000.00View SEC Filing  
9/27/2017David NaglerSVPSell3,750$30.00$112,500.003,750View SEC Filing  
9/25/2017Louis G LangeDirectorSell18,000$28.32$509,760.00453,393View SEC Filing  
9/18/2017Matthew R PattersonCEOSell10,000$25.06$250,600.001,542View SEC Filing  
9/15/2017David NaglerSVPSell3,750$25.00$93,750.003,750View SEC Filing  
9/7/2017Orbimed Advisors LlcMajor ShareholderSell5,000$22.35$111,750.00View SEC Filing  
9/1/2017Suyash PrasadVPSell8,000$21.44$171,520.008,000View SEC Filing  
8/24/2017Mary NewmanSVPSell10,000$20.00$200,000.0010,000View SEC Filing  
7/13/2017Matthew R PattersonCEOSell15,000$20.00$300,000.00View SEC Filing  
7/12/2017Matthew R PattersonCEOSell2,850$20.00$57,000.00View SEC Filing  
6/26/2017Louis G LangeDirectorSell15,000$19.78$296,700.00470,799View SEC Filing  
4/24/20175Am Partners Iii, LlcInsiderBuy172,413$14.50$2,499,988.50View SEC Filing  
7/25/2016James E FlynnInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
7/25/2016Orbimed Advisors LlcDirectorBuy33,334$15.00$500,010.00View SEC Filing  
7/25/2016Versant Ventures Iv, LlcMajor ShareholderBuy35,000$15.00$525,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Audentes Therapeutics (NASDAQ BOLD) News Headlines

Source:
DateHeadline
Audentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.92 Per ShareAudentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.92 Per Share
www.americanbankingnews.com - February 15 at 11:10 AM
Audentes Therapeutics (BOLD) Coverage Initiated by Analysts at MizuhoAudentes Therapeutics (BOLD) Coverage Initiated by Analysts at Mizuho
www.americanbankingnews.com - February 12 at 8:28 PM
Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar SyndromeAudentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
finance.yahoo.com - February 12 at 8:49 AM
Short Interest in Audentes Therapeutics Inc (BOLD) Rises By 71.6%Short Interest in Audentes Therapeutics Inc (BOLD) Rises By 71.6%
www.americanbankingnews.com - February 11 at 1:52 AM
Audentes Therapeutics (BOLD) Rating Increased to Hold at Zacks Investment ResearchAudentes Therapeutics (BOLD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 9 at 7:16 PM
Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare ConferenceAudentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 9:12 AM
Audentes Therapeutics (BOLD) Earns Buy Rating from HC WainwrightAudentes Therapeutics (BOLD) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - February 8 at 12:12 AM
Audentes Therapeutics Inc (BOLD) Receives Consensus Rating of "Buy" from AnalystsAudentes Therapeutics Inc (BOLD) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 5 at 1:28 AM
Gene therapy stocks tank after leading scientist reveals safety concerns; Solid Bioscience down 15%Gene therapy stocks tank after leading scientist reveals safety concerns; Solid Bioscience down 15%
www.marketwatch.com - January 30 at 4:46 PM
Audentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters Option to Purchase Additional SharesAudentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - January 29 at 4:43 PM
Audentes Therapeutics Announces Proposed Public Offering of Common StockAudentes Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 23 at 4:23 PM
Zacks Investment Research Lowers Audentes Therapeutics (BOLD) to SellZacks Investment Research Lowers Audentes Therapeutics (BOLD) to Sell
www.americanbankingnews.com - January 22 at 7:52 PM
Audentes Therapeutics Inc (BOLD) Given Average Recommendation of "Buy" by BrokeragesAudentes Therapeutics Inc (BOLD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 11 at 1:58 AM
Audentes Therapeutics Inc Expected to Post FY2022 Earnings of $12.83 Per Share (BOLD)Audentes Therapeutics Inc Expected to Post FY2022 Earnings of $12.83 Per Share (BOLD)
www.americanbankingnews.com - January 8 at 9:40 PM
Audentes Therapeutics (BOLD) Buy Rating Reiterated at William BlairAudentes Therapeutics' (BOLD) Buy Rating Reiterated at William Blair
www.americanbankingnews.com - January 7 at 9:58 AM
Raymond James Financial Reiterates "Hold" Rating for Audentes Therapeutics (BOLD)Raymond James Financial Reiterates "Hold" Rating for Audentes Therapeutics (BOLD)
www.americanbankingnews.com - January 5 at 8:20 AM
Audentes Therapeutics (BOLD) Price Target Increased to $44.00 by Analysts at BMO Capital MarketsAudentes Therapeutics (BOLD) Price Target Increased to $44.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - January 5 at 7:28 AM
Biotech Stock Rockets To Record On Gene Therapy Trial In ChildrenBiotech Stock Rockets To Record On Gene Therapy Trial In Children
finance.yahoo.com - January 4 at 5:37 PM
Audentes Therapeutics Pulls Off Positive Interim ResultsAudentes Therapeutics Pulls Off Positive Interim Results
finance.yahoo.com - January 4 at 5:37 PM
Audentes Therapeutics (BOLD) PT Raised to $56.00 at WedbushAudentes Therapeutics (BOLD) PT Raised to $56.00 at Wedbush
www.americanbankingnews.com - January 4 at 5:14 PM
Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular MyopathyAudentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
finance.yahoo.com - January 4 at 9:11 AM
Audentes Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceAudentes Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 8:23 AM
Audentes Therapeutics Inc (BOLD) Director Sells $555,840.00 in StockAudentes Therapeutics Inc (BOLD) Director Sells $555,840.00 in Stock
www.americanbankingnews.com - December 28 at 3:42 PM
-$0.92 Earnings Per Share Expected for Audentes Therapeutics Inc (BOLD) This Quarter-$0.92 Earnings Per Share Expected for Audentes Therapeutics Inc (BOLD) This Quarter
www.americanbankingnews.com - December 27 at 1:08 AM
Audentes Therapeutics (BOLD) Stock Rating Upgraded by BidaskClubAudentes Therapeutics (BOLD) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 24 at 10:02 AM
Audentes Therapeutics (BOLD) Coverage Initiated by Analysts at HC WainwrightAudentes Therapeutics (BOLD) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - December 20 at 8:06 PM
Audentes Therapeutics Inc (BOLD) Receives Average Rating of "Hold" from BrokeragesAudentes Therapeutics Inc (BOLD) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 17 at 2:20 AM
Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of DirectorsAudentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors
finance.yahoo.com - December 13 at 9:26 AM
Audentes Therapeutics (BOLD) Lowered to Buy at BidaskClubAudentes Therapeutics (BOLD) Lowered to Buy at BidaskClub
www.americanbankingnews.com - December 10 at 5:14 PM
Audentes Therapeutics Inc (BOLD) VP Suyash Prasad Sells 8,000 SharesAudentes Therapeutics Inc (BOLD) VP Suyash Prasad Sells 8,000 Shares
www.americanbankingnews.com - December 5 at 6:48 PM
Audentes Therapeutics (BOLD) Receives New Coverage from Analysts at BMO Capital MarketsAudentes Therapeutics (BOLD) Receives New Coverage from Analysts at BMO Capital Markets
www.americanbankingnews.com - December 5 at 12:38 PM
Audentes Therapeutics (BOLD) Rating Lowered to Sell at ValuEngineAudentes Therapeutics (BOLD) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 9:26 PM
Audentes Therapeutics, Inc. (BOLD) Given Consensus Rating of "Hold" by BrokeragesAudentes Therapeutics, Inc. (BOLD) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 22 at 1:34 AM
Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular MyopathyAudentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular Myopathy
finance.yahoo.com - November 21 at 3:36 PM
Zacks: Analysts Expect Audentes Therapeutics, Inc. (BOLD) to Post -$0.90 Earnings Per ShareZacks: Analysts Expect Audentes Therapeutics, Inc. (BOLD) to Post -$0.90 Earnings Per Share
www.americanbankingnews.com - November 21 at 1:26 PM
Audentes Therapeutics, Inc. (BOLD) Forecasted to Post FY2017 Earnings of ($3.44) Per ShareAudentes Therapeutics, Inc. (BOLD) Forecasted to Post FY2017 Earnings of ($3.44) Per Share
www.americanbankingnews.com - November 20 at 3:44 AM
FY2017 EPS Estimates for Audentes Therapeutics, Inc. Decreased by Analyst (BOLD)FY2017 EPS Estimates for Audentes Therapeutics, Inc. Decreased by Analyst (BOLD)
www.americanbankingnews.com - November 17 at 9:44 PM
Audentes Therapeutics, Inc. (BOLD) Downgraded by Zacks Investment Research to SellAudentes Therapeutics, Inc. (BOLD) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - November 17 at 9:18 PM
Insider Selling: Audentes Therapeutics, Inc. (BOLD) SVP Sells 10,000 Shares of StockInsider Selling: Audentes Therapeutics, Inc. (BOLD) SVP Sells 10,000 Shares of Stock
www.americanbankingnews.com - November 17 at 8:40 PM
Equities Analysts Offer Predictions for Audentes Therapeutics, Inc.s Q3 2017 Earnings (BOLD)Equities Analysts Offer Predictions for Audentes Therapeutics, Inc.'s Q3 2017 Earnings (BOLD)
www.americanbankingnews.com - November 17 at 7:10 PM
Edited Transcript of BOLD earnings conference call or presentation 14-Nov-17 9:30pm GMTEdited Transcript of BOLD earnings conference call or presentation 14-Nov-17 9:30pm GMT
finance.yahoo.com - November 16 at 5:04 PM
Audentes Therapeutics (BOLD) CEO Matt Patterson on Q3 2017 Results - Earnings Call TranscriptAudentes Therapeutics' (BOLD) CEO Matt Patterson on Q3 2017 Results - Earnings Call Transcript
www.msn.com - November 16 at 12:05 PM
Audentes Therapeutics reports 3Q lossAudentes Therapeutics reports 3Q loss
www.cnbc.com - November 16 at 12:05 PM
Audentes Therapeutics, Inc. (BOLD) Posts  Earnings Results, Hits EstimatesAudentes Therapeutics, Inc. (BOLD) Posts Earnings Results, Hits Estimates
www.americanbankingnews.com - November 16 at 9:16 AM
Audentes Therapeutics, Inc. (BOLD) Rating Reiterated by Leerink SwannAudentes Therapeutics, Inc. (BOLD) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - November 15 at 11:42 AM
Audentes Therapeutics, Inc. to Host Earnings CallAudentes Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 14 at 5:09 PM
Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateAudentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 14 at 5:09 PM
Audentes Therapeutics to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 14, 2017Audentes Therapeutics to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 14, 2017
finance.yahoo.com - November 7 at 7:35 PM
Audentes Therapeutics, Inc. (BOLD) Scheduled to Post Earnings on WednesdayAudentes Therapeutics, Inc. (BOLD) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:08 AM
Audentes Therapeutics, Inc. (BOLD) Receives Consensus Recommendation of "Buy" from BrokeragesAudentes Therapeutics, Inc. (BOLD) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 28 at 2:06 AM

SEC Filings

Audentes Therapeutics (NASDAQ:BOLD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Audentes Therapeutics (NASDAQ:BOLD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Audentes Therapeutics (NASDAQ BOLD) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.